Table 4.
Univariate prognostic analyses in pT4 colon and rectosigmoid cancer (N = 130)
| Parameters | Categories | Number (%) | 5-year OS (%) | p value | 5-year RFS (%) | p value |
|---|---|---|---|---|---|---|
| Age (years) | ≥ 74 | 30 (23.1) | 59.0 | 0.003 | 63.3 | 0.791 |
| < 74 | 100 (76.9) | 82.7 | 63.6 | |||
| Gender | Male | 73 (56.2) | 70.5 | 0.003 | 55.5 | 0.033 |
| Female | 57 (43.8) | 85.7 | 73.6 | |||
| Body mass index | ≥ 21 | 82 (63.1) | 77.7 | 0.103 | 60.4 | 0.388 |
| < 21 | 48 (36.9) | 76.5 | 68.8 | |||
| ASA scorea | 1/2 | 118 (90.8) | 78.3 | 0.178 | 64.0 | 0.597 |
| 3 | 12 (9.2) | 66.7 | 58.3 | |||
| CEA (ng/ml) | ≥ 4.8 | 60 (46.2) | 67.8 | 0.011 | 55.8 | 0.070 |
| < 4.8 | 70 (53.8) | 85.5 | 69.9 | |||
| Tumor location | Right-sided | 55 (42.3) | 64.1 | 0.068 | 65.1 | 0.913 |
| Left-sided | 75 (57.7) | 86.5 | 62.5 | |||
| Anastomosis | DST | 68 (52.3) | 86.6 | 0.200 | 60.1 | 0.609 |
| FEEA | 62 (47.7) | 66.6 | 67.5 | |||
| cT | cT3 | 32 (24.6) | 74.2 | 0.824 | 65.3 | 0.822 |
| cT4a | 98 (75.4) | 78.2 | 62.9 | |||
| cN | cN0/1 | 125 (96.2) | 77.2 | 0.485 | 63.9 | 0.617 |
| cN2 | 5 (3.8) | 80.0 | 50.0 | |||
| pT | pT4a | 125 (96.2) | 76.4 | 0.280b | 62.0 | 0.128b |
| pT4b | 5 (3.8) | 100.0 | 100.0 | |||
| pN | pN0/1 | 103 (79.2) | 78.2 | 0.275 | 68.8 | 0.045 |
| pN2 | 27 (20.8) | 73.7 | 41.7 | |||
| Harvested lymph nodes | ≥ 17 | 79 (60.8) | 81.9 | 0.169 | 64.1 | 0.871 |
| < 17 | 51 (39.2) | 70.4 | 62.6 | |||
| Lymph node ratioc | ≥ 0.06 | 67 (51.5) | 69.6 | < 0.001 | 42.2 | < 0.001 |
| < 0.06 | 63 (48.5) | 85.3 | 85.7 | |||
| Tumor differentiation | Well/moderately | 120 (92.3) | 78.8 | 0.135 | 65.7 | 0.097 |
| Poorly | 10 (7.7) | 56.3 | 34.3 | |||
| Lymphatic invasion | ly0/1/2 | 115 (88.5) | 80.6 | 0.009 | 68.5 | 0.003 |
| ly3 | 15 (11.5) | 50.6 | 21.8 | |||
| Vascular invasion | v0/1/2 | 97 (74.6) | 83.2 | 0.038 | 68.6 | 0.025 |
| v3 | 33 (25.4) | 59.4 | 48.5 | |||
| Tumor diameter (mm) | ≥ 38 | 87 (66.9) | 79.8 | 0.047 | 67.5 | 0.217 |
| < 38 | 43 (33.1) | 71.9 | 55.4 | |||
| Adjuvant chemotherapy | Absence | 63 (48.5) | 78.9 | 0.602 | 74.4 | 0.024 |
| Presence | 67 (51.5) | 75.7 | 53.1 | |||
| Operative time (min) | ≥ 230 | 40 (30.8) | 79.1 | 0.506 | 61.4 | 0.855 |
| < 230 | 90 (69.2) | 76.4 | 64.3 | |||
| Blood loss (ml) | ≥ 35 | 39 (30.0) | 81.6 | 0.401 | 71.3 | 0.318 |
| < 35 | 91 (70.0) | 75.5 | 60.2 | |||
| Conversion to open surgey | Absence | 125 (96.2) | 77.2 | 0.782 | 62.2 | 0.156b |
| Presence | 5 (3.8) | 80.0 | 100.0 | |||
| Morbidity (Clavien–Dindod ≥ Grade II) | Absence | 117 (90.0) | 77.3 | 0.456 | 62.0 | 0.292 |
| Presence | 13 (10.0) | 76.2 | 76.9 |
DST double stapling technique, FEEA functional end-to-end anastomosis, RFS recurrence-free survival, OS overall survival
Bold values was defined reaching p values < 0.1 in all variables
aAmerican Society of Anesthesiologists score
bLog-rank-test
cThe ratio of metastatic lymph nodes to total number of harvested lymph nodes
dClavien–Dindo classification